Page 24 - ITPS-5-2
P. 24

18    INNOSC Theranostics and Pharmacological Sciences, 2022, Vol. 5, No. 2          Govender and Hodkinson

            Table 2. ANCA testing according to indication guidelines per department
            Department          Total        1999 Guideline indication   Common non-guideline indications
                               requests       No              Yes
                               n=790      n=598 n (%)     n=192 n (%)
            Cardiology            4          4 (100)         0 (0)       Valvular heart disease
            Critical care        22         15 (68.2)       7 (31.8)     AKI, seizures, encephalopathy
            Dermatology          10         6 (60.0)        4 (40.0)     Non-specific rash
            Otolaryngology       31         27 (87.1)       4 (12.9)     Sensory-neural hearing loss, vocal cord paralysis
            Gastroenterology      3          3 (100)         0 (0)       IBD
            General Medicine     272       173 (63.6)       99 (36.4)    AKI, stroke
            Nephrology           30         15 (50.0)       15 (50.0)    AKI
            Neurology            100        70 (70.0)       30 (30.0)    Stroke, encephalopathy
            Obgyn                25         20 (80.0)       5 (20.0)     Recurrent pregnancy losses, POF
            Ophthalmology        105        83 (79.1)       22 (20.9)    Uveitis, optic neuritis
            Orthopedics          28         28 (100)         0 (0)       Trigger finger, CTS, arthritis
            Psychiatry            2          2 (100)         0 (0)       Encephalopathy, psychosis
            Pulmonology          35         32 (91.4)        3 (8.6)     ILD, poorly controlled asthma, PHT
            Rheumatology         25         23 (92.0)        2 (8.0)     Raynaud’s phenomenon, arthritis
            Surgery              95         94 (98.9)        1 (1.1)     CLI, vascular aneurysms
            Trauma                3          3 (100)         0 (0)       ICA dissection, TBI
            Abbreviations: AKI: Acute kidney injury, CLI: Critical limb ischemia, CTS: Carpal tunnel syndrome, IBD: Inflammatory bowel disease,
            ICA: Internal carotid artery, ILD: Interstitial lung disease, Obgyn: Obstetrics and gynecology, PHT: Pulmonary hypertension, POF:
            Premature ovarian failure, TBI: Traumatic brain injury.

            Table 3. Details of ten patients with anti-neutrophil cytoplasmic antibody-associated vasculitis

            Gender     Age    Ethnicity   Department            AAV type     MPO      PR3      Guideline indication
            M           55    Mixed       Medicine              GPA          Neg      Neg      Yes
            F           49    Mixed       Medicine              RLV          Pos      Neg      Yes
            F           37    Mixed       Medicine              RLV          Pos      Neg      Yes
            M           81    Caucasian   Medicine              RLV          Pos      Neg      Yes
            F           71    Mixed       Medicine              RLV          Pos      Neg      Yes
            M           39    Mixed       Medicine, Nephrology  RLV          Neg      Pos      Yes
            F           58    African     Medicine, Nephrology  RLV          Neg      Neg      Yes
            F           58    Mixed       Nephrology            RLV          Neg      Neg      Yes
            F           29    Mixed       Nephrology            RLV          Neg      Neg      Yes
            F           68    Mixed       Medicine              RLV          Neg      Neg      Yes
            Abbreviations: AAV: Anti-neutrophil cytoplasmic antibody-associated vasculitis, F: Female, GPA: Polyangiitis, M: Male,
            MPO: Anti-myeloperoxidase antibody, Neg: Negative, Pos: Positive, PR3: Anti-proteinase 3 antibody, RLV: Renal limited vasculitis.

           lower than what has been described elsewhere due     ZAR208,275  on tests  for  non-indicated  clinical
           to the high number of false positive tests observed   conditions.
           in  our  setting.  The  sensitivity,  specificity,  PPV,
           and NPV were 50.0%, 95.1%, 35.7%, and 97.2%,         4. Discussion
           respectively. The total estimated cost of ANCA tests   Due to its multi-system heterogeneous presentation,
           throughout the year amounted  to ZAR274,046,         insidious onset, and rarity, small vessel vasculitis
           with ZAR17,490  spent on duplicate  testing and      poses a diagnostic challenge. As a result, the ANCA

                                                    ©2022 AccScience Publishing
   19   20   21   22   23   24   25   26   27   28   29